Described herein are compositions for treating dermatological conditions, such as skin conditions, as well as neuropathological conditions and disorders, particularly those requiring relief from pain and physical discomfort. The compositions as described may be topically or transdermally administered. In some aspects, the compositions and products comprise a pharmaceutically acceptable amount of at least one analgesic component and a cannabis component and are useful to relieve acute or chronic pain, inflammation, and the like, following application.

Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.

Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.

A topical ophthalmological composition includes a multikinase inhibitor as an active pharmaceutical ingredient, and perfluorohexyloctane (F6H8) as a liquid vehicle. The multikinase inhibitor inhibits vascular endothelial growth factor receptors (VEGFRs). A method for treating an ophthalmological disorder includes: providing a topical ophthalmological composition containing a multikinase inhibitor at a concentration of about 0.01-10% (w/v); and treating a patient with the topical ophthalmological composition for treating the ophthalmological disorder.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic agents to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.

A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm).

A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm).

Invention deals with a macular carotenoid formulation comprising Carotenoids, Lutein, Zeaxanthin, Meso Zeaxanthin, Beta Carotene, Alpha Carotene, Lycopene and Cryptoxanthin in a synergistic combination. The formulation helps in increasing macular pigment optical density (MPOD) related to prevention of age-related macular degeneration (ARMD). The formulation is used as a nutrient, nutraceutical or dietary supplement. The dietary supplement may be formulated as soft gel capsules, two-piece hard-shell capsules, liquid-fill capsules, tablets, effervescent granules, gummies, powder mixes, stick packs, beverages, emulsions, bakery products, dairy products, tinctures, oil suspensions, bead-lets, powders, cold water-soluble powders, emulsions and granules or any combination thereof. The present invention can be used for the development of functional food, dietary plan and as a nutritional supplement. In exemplary embodiment, formulation is available in forms like oil suspension, beadlets, powders, cold water-soluble powders, emulsions and granules.